Edition:
India

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

32.25USD
10:11pm IST
Change (% chg)

$-1.15 (-3.44%)
Prev Close
$33.40
Open
$33.35
Day's High
$33.44
Day's Low
$31.78
Volume
773,654
Avg. Vol
541,858
52-wk High
$33.99
52-wk Low
$17.61

Chart for

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

UPDATE 1-Fresenius says Akorn troubles could continue into next year

FRANKFURT, Nov 2 German healthcare group Fresenius SE said on Thursday that weakness at Akorn , the U.S. maker of liquid generic drugs it has agreed to buy, could continue into next year but the deal was still worth it over the longer term.

02 Nov 2017

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc , has resigned as chairman of drugmaker Akorn Inc , just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

01 Nov 2017

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc, has resigned as chairman of drugmaker Akorn Inc, just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

01 Nov 2017

Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

27 Oct 2017

Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

27 Oct 2017

UPDATE 3-Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON, Oct 26 The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

27 Oct 2017

Senvest Management shorting drug stocks Insys, Akorn, Fresenius

TEL AVIV, Oct 3 New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday,

03 Oct 2017

Exclusive: Prosecutors identify Insys founder as unindicted co-conspirator in opioid case

BOSTON U.S. prosecutors have identified Insys Therapeutics Inc's billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document.

15 Sep 2017

Exclusive: Prosecutors identify Insys founder as unindicted co-conspirator in opioid case

BOSTON U.S. prosecutors have identified Insys Therapeutics Inc's billionaire founder as an unindicted co-conspirator in a case accusing six former executives and managers of participating in a scheme that involved bribing doctors to prescribe a fentanyl-based drug, according to a court document.

15 Sep 2017

BRIEF-Fresenius SE says Akorn shareholders approved merger

* At yesterday's special meeting, shareholders of Akorn, Inc., have approved merger agreement with fresenius kabi, with 83.9 percent of outstanding shares being voted in favour of transaction. Source text for Eikon: Further company coverage:

20 Jul 2017

Earnings vs. Estimates